Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-004 in C9orf72-associated ALS or FTD
NCT04931862Phase 2Terminated
- Sponsor
- Wave Life Sciences
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of WVE-004 in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (4 arms), sponsored by Wave Life Sciences. Primary endpoint: Proportion of patients with adverse events (AEs). Started Jun 2021; status: terminated.
02
Drugs
WVE-004
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT04931862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931862.